BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment
In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA (zanubrutinib). This marks the treatment as the first and only BTK inhibitor approved for adult patients in the U.S. who have undergone two or more lines […]